Interleukin‐25: New perspective and state‐of‐the‐art in cancer prognosis and treatment approaches

Autor: Lakshmi Thangavelu, Arezoo Gowhari Shabgah, Jamshid Gholizadeh Navashenaq, Azwar Amir, Zhanna R. Gardanova, Maryam Ebrahimi Nik, Majid Ahmadi, Angelina Olegovna Zekiy
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
0301 basic medicine
Cancer Research
medicine.medical_treatment
Apoptosis
Review
Mice
0302 clinical medicine
Neoplasms
Interleukin 25
Tumor Microenvironment
cytokine
Bile
Medicine
RC254-282
Cancer Biology
Cancer
Immunity
Cellular
Receptors
Interleukin-17
Cell Cycle
Interleukin-17
Liver Neoplasms
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Cell cycle
Prognosis
Cytokine
Oncology
030220 oncology & carcinogenesis
Disease Progression
biomarker
Female
Signal Transduction
Carcinoma
Hepatocellular
Reviews
Antineoplastic Agents
Breast Neoplasms
IL‐17E
03 medical and health sciences
Immune system
Biomarkers
Tumor
Animals
Humans
Radiology
Nuclear Medicine and imaging
Benzofurans
Cell Proliferation
Tumor microenvironment
Tissue Extracts
business.industry
Prostatic Neoplasms
IL‐25
medicine.disease
Biomarker (cell)
030104 developmental biology
Tumor progression
Cancer research
business
Zdroj: Cancer Medicine, Vol 10, Iss 15, Pp 5191-5202 (2021)
Cancer Medicine
ISSN: 2045-7634
Popis: Cancer is a leading cause of death which imposes a substantial financial burden. Among the several mechanisms involved in cancer progression, imbalance of immune cell‐derived factors such as cytokines and chemokines plays a central role. IL‐25, as a member of the IL‐17 cytokine subfamily, exerts a paradoxical role in cancer, including tumor supportive and tumor suppressive. Hence, we have tried to clarify the role of IL‐25 and its receptor in tumor progression and cancer prognosis. It has been confirmed that IL‐25 exerts a tumor‐suppressive role through inducing infiltration of eosinophils and B cells into the tumor microenvironment and activating the apoptotic pathways. In contrast, the tumor‐supportive function has been implemented by activating inflammatory cascades, promoting cell cycle, and inducing type‐2 immune responses. Since IL‐25 has been dysregulated in tumor tissues and this dysregulation is involved in cancer development, its examination can be used as a tumor diagnostic and prognostic biomarker. Moreover, IL‐25‐based therapeutic approaches have shown promising results in cancer inhibition. In cancers in which IL‐25 has a tumor‐suppressive function, employing IL‐25‐enhancing approaches, such as Virulizin® and dihydrobenzofuran administration, has potentially inhibited tumor cell growth. On the other hand, in the case of IL‐25‐dependent tumor progression, using IL‐25 blocking methods, including anti‐IL‐25 antibodies, might be a complementary approach to the other anticancer agent. Collectively, it is hoped, IL‐25 might be a promising target in cancer treatment.
This study is focused on the role of IL‐25 in cancer development. It has been shown that IL‐25 exerts conflicting functions in the tumor microenvironment. Using IL‐25‐based therapies might introduce novel approaches in cancer treatment.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje